Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
serplulimab + decitabine + oxaliplatin + capecitabine
- Development stage
- Unknown
- Lead developer
- Henlius
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Serplulimab + decitabine + oxaliplatin + capecitabine is an investigational neoadjuvant combination regimen being evaluated for the treatment of locally advanced colorectal cancer. This multi-drug strategy combines the PD-1 inhibitor serplulimab with the hypomethylating agent decitabine and the CAPOX chemotherapy backbone (oxaliplatin and capecitabine). Serplulimab is a monoclonal antibody that blocks the PD-1 immune checkpoint to restore anti-tumor T-cell activity. Decitabine, a DNA methyltransferase inhibitor, acts as an epigenetic sensitizer intended to enhance tumor immunogenicity and improve the response to immunotherapy, particularly in pMMR/MSS tumors that are typically resistant to checkpoint blockade. Oxaliplatin and capecitabine provide cytotoxic effects and induce immunogenic cell death, further priming the tumor microenvironment for an immune response. The regimen is currently being studied in Phase II clinical trials sponsored by the Tianjin Medical University Cancer Institute and Hospital.
- Other names
- serplulimab + decitabine + CAPOXserplulimab + decitabine + XELOX
02
Targets
DNMT (DNA methyltransferase)PDCD1 (Programmed cell death protein 1 receptor)DNATS (Thymidylate synthase)
Beyond the preview
Go deeper on serplulimab + decitabine + oxaliplatin + capecitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on serplulimab + decitabine + oxaliplatin + capecitabine.